PPLPHARMA — Piramal Pharma Cashflow Statement
0.000.00%
- IN₹283.81bn
- IN₹327.14bn
- IN₹81.71bn
Annual cashflow statement for Piramal Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | R2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | 3,491 | 4,410 | -1,675 | 1,198 |
Depreciation | ||||
Non-Cash Items | -520 | 2,009 | 4,588 | 5,353 |
Unusual Items | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | -3,234 | -3,850 | -4,841 | -3,911 |
Change in Accounts Receivable | ||||
Change in Inventories | ||||
Change in Other Assets | ||||
Change in Accounts Payable | ||||
Change in Other Liabilities | ||||
Other Operating Cash Flow | ||||
Cash from Operating Activities | 347 | 8,432 | 4,839 | 10,045 |
Capital Expenditures | -581 | -8,895 | -9,648 | -7,120 |
Purchase of Fixed Assets | ||||
Other Investing Cash Flow Items | -43,248 | -9,226 | -3,740 | 2,780 |
Acquisition of Business | ||||
Sale of Fixed Assets | ||||
Sale/Maturity of Investment | ||||
Purchase of Investments | ||||
Other Investing Cash Flow | ||||
Cash from Investing Activities | -43,829 | -18,121 | -13,388 | -4,340 |
Financing Cash Flow Items | 8,816 | -1,445 | -2,781 | -4,837 |
Other Financing Cash Flow | ||||
Total Cash Dividends Paid | ||||
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 44,942 | 7,942 | 8,178 | -4,224 |
Foreign Exchange Effects | ||||
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | 1,460 | -1,768 | -320 | 1,660 |